Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T64410
|
||||
Former ID |
TTDS00182
|
||||
Target Name |
D-alanyl-D-alanine carboxypeptidase
|
||||
Gene Name |
vanYB
|
||||
Synonyms |
D-alanyl-D-alanine carboxypeptidase-transpeptidase; DD-carboxypeptidase; DD-peptidase; vanYB
|
||||
Target Type |
Successful
|
||||
Disease | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99] | ||||
Gram-positive bacterial infection [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104] | |||||
Function |
Vancomycin-inducible, penicillin-resistant, DD- carboxypeptidase that hydrolyzes depsipeptide- and D-alanyl-D- alanine-containing peptidoglycan precursors. Insensitive to beta- lactams.
|
||||
BioChemical Class |
Peptidase
|
||||
Target Validation |
T64410
|
||||
UniProt ID | |||||
EC Number |
EC 3.4.16.4
|
||||
Sequence |
MEKSNYHSNVNHHKRHMKQSGEKRAFLWAFIISFTVCTLFLGWRLVSVLEATQLPPIPAT
HTGSGTGVAENPEENTLATAKEQGDEQEWSLILVNRQNPIPAQYDVELEQLSNGERIDIR ISPYLQDLFDAARADGVYPIVASGYRTTEKQQEIMDEKVAEYKAKGYTSAQAKAEAETWV AVPGTSEHQLGLAVDINADGIHSTGNEVYRWLDENSYRFGFIRRYPPDKTEITGVSNEPW HYRYVGIEAATKIYHQGLCLEEYLNTEK |
||||
Drugs and Mode of Action | |||||
Drug(s) | B-Lactams | Drug Info | Approved | Bacterial infections | [536854] |
Cefalotin | Drug Info | Approved | Bacterial infections | [549818] | |
Cefotaxime | Drug Info | Approved | Bacterial infections | [538212] | |
Cephalosporin | Drug Info | Approved | Bacterial infections | [550623] | |
TD-1792 | Drug Info | Phase 2 | Gram-positive bacterial infection | [521976] | |
Inhibitor | 2-[(Dioxidophosphino)Oxy]Benzoate | Drug Info | [551393] | ||
3-boronobenzoic acid | Drug Info | [530358] | |||
5-boronothiophene-2-carboxylic acid | Drug Info | [530358] | |||
B-Lactams | Drug Info | [536854] | |||
Benzo[c][1,2]oxaborol-1(3H)-ol | Drug Info | [530358] | |||
Cefalotin | Drug Info | [537844] | |||
Cefotaxime | Drug Info | [536459], [537844] | |||
Cephalosporin C | Drug Info | [551391] | |||
D-Alanine | Drug Info | [551393] | |||
Formaldehyde | Drug Info | [551393] | |||
Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine | Drug Info | [551393] | |||
NITROCEFIN | Drug Info | [551374] | |||
Phenyl Boronic acid | Drug Info | [530358] | |||
TD-1792 | Drug Info | [536773] | |||
Binder | Cephalosporin | Drug Info | [535110] | ||
References | |||||
Ref 521976 | ClinicalTrials.gov (NCT00442832) TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection. U.S. National Institutes of Health. | ||||
Ref 536854 | Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. | ||||
Ref 530358 | J Med Chem. 2009 Oct 8;52(19):6097-106.Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. | ||||
Ref 535110 | A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31. | ||||
Ref 536459 | Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307. | ||||
Ref 536773 | How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. | ||||
Ref 536854 | Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6. | ||||
Ref 537844 | Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.